John A. Flygare

6.7k total citations · 1 hit paper
44 papers, 3.4k citations indexed

About

John A. Flygare is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, John A. Flygare has authored 44 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 19 papers in Organic Chemistry and 12 papers in Oncology. Recurrent topics in John A. Flygare's work include Cell death mechanisms and regulation (10 papers), Click Chemistry and Applications (6 papers) and Ubiquitin and proteasome pathways (5 papers). John A. Flygare is often cited by papers focused on Cell death mechanisms and regulation (10 papers), Click Chemistry and Applications (6 papers) and Ubiquitin and proteasome pathways (5 papers). John A. Flygare collaborates with scholars based in United States, France and Switzerland. John A. Flygare's co-authors include Wayne J. Fairbrother, Barry M. Trost, Linda O. Elliott, Domagoj Vucic, Kurt Deshayes, Kerry Zobel, Eugene Varfolomeev, Heidi J.A. Wallweber, Thomas H. Pillow and Jasmin N. Dynek and has published in prestigious journals such as Cell, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

John A. Flygare

43 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis

2007 1.0k citations Eugene Varfolomeev, John W. Blankenship et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John A. Flygare United States	26	2.3k	907	679	647	428	44	3.4k
Darren R. Veach United States	26	1.5k 0.7×	1.0k 1.1×	439 0.6×	394 0.6×	249 0.6×	58	4.0k
Andrea G. Cochran United States	32	3.4k 1.5×	507 0.6×	457 0.7×	532 0.8×	287 0.7×	42	4.2k
Arnold C. Satterthwait United States	28	2.0k 0.9×	245 0.3×	484 0.7×	677 1.0×	250 0.6×	51	3.1k
Andrew G. Stephen United States	32	2.8k 1.2×	681 0.8×	315 0.5×	251 0.4×	489 1.1×	92	3.6k
Nouri Neamati United States	26	1.1k 0.5×	923 1.0×	635 0.9×	302 0.5×	174 0.4×	50	2.5k
Gregory H. Bird United States	32	3.5k 1.5×	701 0.8×	701 1.0×	313 0.5×	157 0.4×	59	4.1k
Joseph L. Kim United States	14	2.9k 1.3×	697 0.8×	230 0.3×	224 0.3×	317 0.7×	21	3.9k
Anne M. Hassell United States	21	1.6k 0.7×	1.0k 1.1×	585 0.9×	208 0.3×	408 1.0×	32	2.9k
Jennifer L. Meagher United States	33	2.2k 1.0×	708 0.8×	453 0.7×	349 0.5×	234 0.5×	53	2.9k
Patrick Chêne Switzerland	30	3.9k 1.7×	2.0k 2.2×	676 1.0×	235 0.4×	491 1.1×	102	5.1k

Countries citing papers authored by John A. Flygare

Since Specialization

Citations

This map shows the geographic impact of John A. Flygare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Flygare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Flygare more than expected).

Fields of papers citing papers by John A. Flygare

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Flygare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Flygare. The network helps show where John A. Flygare may publish in the future.

Co-authorship network of co-authors of John A. Flygare

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Flygare. A scholar is included among the top collaborators of John A. Flygare based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Flygare. John A. Flygare is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chernyak, Natalia, Saraswathi Naravula, Ying Chen, et al.. (2024). Discovery and Evaluation of TLR-Targeted Immune Agonists. Journal of Medicinal Chemistry. 67(18). 16222–16234. 2 indexed citations

Hugelshofer, Cedric L., Ian Knemeyer, Allegra T. Aron, et al.. (2023). In vivo bioluminescence imaging of labile iron in xenograft models and liver using FeAL-1, an iron-activatable form of D-luciferin. Cell chemical biology. 30(11). 1468–1477.e6. 7 indexed citations

Xie, Minli, Harvey Wong, Hank La, et al.. (2019). Cyclodextrin Reduces Intravenous Toxicity of a Model Compound. Journal of Pharmaceutical Sciences. 108(6). 1934–1943. 13 indexed citations

Zheng, Bing, Shang‐Fan Yu, Geoffrey Del Rosario, et al.. (2018). An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia. Clinical Cancer Research. 25(4). 1358–1368. 49 indexed citations

Hewings, David S., Johanna Heideker, P. Taylur, et al.. (2018). Reactive-site-centric chemoproteomics identifies a distinct class of deubiquitinase enzymes. Nature Communications. 9(1). 1162–1162. 71 indexed citations

Hewings, David S., John A. Flygare, Matthew Bogyo, & Ingrid E. Wertz. (2017). Activity‐based probes for the ubiquitin conjugation–deconjugation machinery: new chemistries, new tools, and new insights. FEBS Journal. 284(10). 1555–1576. 94 indexed citations

Gregson, Stephen J., Luke A. Masterson, BinQing Wei, et al.. (2017). Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers. Journal of Medicinal Chemistry. 60(23). 9490–9507. 27 indexed citations

Yu, Shang‐Fan, Bing Zheng, MaryAnn Go, et al.. (2015). A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Clinical Cancer Research. 21(14). 3298–3306. 125 indexed citations

Flygare, John A. & Michelle R. Arkin. (2014). Inhibiting Caspase-6 Activation and Catalytic Activity for Neurodegenerative Diseases. Current Topics in Medicinal Chemistry. 14(3). 319–325. 1 indexed citations

10.

Murray, Jeremy, Anthony M. Giannetti, Micah Steffek, et al.. (2013). Tailoring Small Molecules for an Allosteric Site on Procaspase‐6. ChemMedChem. 9(1). 73–77. 24 indexed citations

11.

Polson, Andrew G., Bing Zheng, MaryAnn Go, et al.. (2013). Abstract 4634: Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin's lymphoma are effective in cell lines resistant to auristatin based ADCs.. Cancer Research. 73(8_Supplement). 4634–4634. 1 indexed citations

12.

Wong, Harvey, Stephen E. Gould, Nageshwar Budha, et al.. (2013). Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist. Drug Metabolism and Disposition. 41(12). 2104–2113. 42 indexed citations

13.

Wong, Harvey, Nageshwar Budha, Kristina West, et al.. (2012). Dogs Are More Sensitive to Antagonists of Inhibitor of Apoptosis Proteins Than Rats and Humans: A Translational Toxicokinetic/Toxicodynamic Analysis. Toxicological Sciences. 130(1). 205–213. 13 indexed citations

14.

Tarrant, Jacqueline M., Gary Cain, Sock-Cheng Lewin-Koh, et al.. (2012). Toxicity Profile of Small-Molecule IAP Antagonist GDC-0152 Is Linked to TNF-α Pharmacology. Toxicological Sciences. 131(1). 247–258. 28 indexed citations

15.

Flygare, John A., Thomas H. Pillow, & Paul A. Aristoff. (2012). Antibody‐Drug Conjugates for the Treatment of Cancer. Chemical Biology & Drug Design. 81(1). 113–121. 178 indexed citations

16.

Cohen, Frederick, Michael F. T. Koehler, Philippe Bergeron, et al.. (2010). Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres. Bioorganic & Medicinal Chemistry Letters. 20(7). 2229–2233. 15 indexed citations

17.

Jin, Hongkui, Renhui Yang, Calvin Ho, et al.. (2007). IAP (inhibitor of apoptosis) antagonist inhibits orthotopic lung tumor growth. Molecular Cancer Therapeutics. 6. 1 indexed citations

18.

Varfolomeev, Eugene, John W. Blankenship, Anna Fedorova, et al.. (2007). IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis. Cell. 131(4). 669–681. 1013 indexed citations breakdown →

19.

Cushing, Timothy D., John A. Flygare, Jay P. Powers, et al.. (2006). Discovery of a novel series of inhibitors of human cytomegalovirus primase. Bioorganic & Medicinal Chemistry Letters. 16(18). 4879–4883. 5 indexed citations

20.

Olivero, Alan G., Charles Eigenbrot, Richard Goldsmith, et al.. (2005). A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo. Journal of Biological Chemistry. 280(10). 9160–9169. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact